-
Substance P: An Assay-Centered Research Framework
2026-09-03
Substance P research requires more than receptor activation: matrix effects, sample handling, and readout quality can determine whether a biological signal is interpretable. This assay-centered framework connects tachykinin biology with rigorous analytical decision-making while clarifying how fluorescence preprocessing concepts can—and cannot—transfer to peptide experiments.
-
T7 RNA Polymerase for mRNA Workflows
2026-09-03
Build promoter-specific RNA synthesis workflows around T7 RNA Polymerase, from linearized plasmid templates to functional mRNA assays. This guide connects practical IVT optimization with the localized p21 mRNA–LNP strategy reported in bladder cancer research, while separating established findings from recommended starting conditions.
-
Cytochalasin D in Corneal Uptake Assays
2026-09-02
Cytochalasin D is a powerful actin polymerization inhibitor for testing whether nanoparticle uptake depends on cytoskeletal remodeling. This article translates corneal epithelial nanoparticle findings into a causal assay framework that separates reduced internalization from nonspecific cellular injury.
-
GSK621: Reframing AMPK Agonism for Translation
2026-09-02
GSK621 offers translational researchers a direct way to interrogate AMPK-driven metabolic remodeling across acute myeloid leukemia and tumor-associated macrophage models. This article connects target engagement, autophagy, apoptosis, and immunometabolism into a practical validation strategy.
-
Mavorixafor in WHIM Syndrome: Phase 3 Evidence
2026-09-01
The reference commentary examines a placebo-controlled phase 3 trial showing that oral CXCR4 antagonism with mavorixafor prolonged neutrophil and lymphocyte availability and reduced infections in patients with WHIM syndrome. Its importance lies in targeting the disease-driving trafficking defect with a practical oral regimen, while leaving longer-term questions about immune normalization, malignancy risk, and lifelong safety unresolved.
-
RSL3, PARP1, and Ferroptosis–Apoptosis Crosstalk
2026-09-01
A 2025 study shows that RSL3 connects ferroptosis with apoptosis through two distinct PARP1-regulatory routes: caspase-dependent cleavage and depletion of full-length PARP1 through altered m6A-dependent translation. The findings provide a mechanistic framework for interpreting RSL3 responses in PARP inhibitor-resistant cancer models and for designing assays that distinguish apoptotic execution from ferroptotic stress.
-
DDI2–NFE2L1 Protects Cells from Ferroptosis
2026-08-31
Ofoghi and colleagues show that ferroptosis triggers proteasome impairment and global hyperubiquitylation, while DDI2-dependent activation of NFE2L1 restores proteasome capacity and improves cell survival. The study identifies the DDI2–NFE2L1–ubiquitin-proteasome axis as a mechanistically supported point for sensitizing cells to ferroptosis, including through the clinical drug nelfinavir.
-
Fucoidan and the Gut–Liver Axis in Chemotherapy Injury
2026-08-31
A 2026 study identifies intestinal barrier failure and neutrophil extracellular traps as linked drivers of irinotecan-induced steatohepatitis. Its findings suggest that Fucoidan may protect the liver indirectly by preserving gut integrity, limiting lipopolysaccharide translocation, and suppressing excessive NET-associated inflammation.
-
α-Bungarotoxin in Translational Cholinergic Research
2026-08-30
α-Bungarotoxin is more than a receptor antagonist: it is a causal probe for testing how α7 nicotinic acetylcholine receptor signaling shapes inflammation, cell death, and tissue function. This article connects nicotinic receptor blockade with recent placental necroptosis findings and offers a practical framework for translational study design.
-
Octyl-α-ketoglutarate for HIF-1α Studies
2026-08-29
Octyl-α-ketoglutarate is a cell-permeable prolyl hydroxylase substrate for testing whether α-ketoglutarate availability changes HIF-1α turnover in metabolically rewired cells. This practical guide converts IDH and TCA-cycle hypotheses into controlled dosing, hypoxia comparisons, and orthogonal readouts, with troubleshooting for solvent, timing, and interpretation.
-
Nelfinavir Mesylate: Virology to Ferroptosis
2026-08-28
Nelfinavir Mesylate is a high-value HIV-1 protease inhibitor for antiviral assays and a mechanistic probe for DDI2–NFE2L1 control of ferroptosis. This workflow-focused guide shows how to separate HIV replication suppression from proteostasis and cell-death effects while improving solubility, controls, and assay interpretation.
-
Ibrexafungerp Against Resistant Candida auris
2026-08-28
Wiederhold and colleagues show that ibrexafungerp retained in vitro activity against fluconazole-resistant Candida auris and improved outcomes in a neutropenic mouse model even when therapy began after infection was established. The study is important because it connects resistance-aware susceptibility testing with an oral glucan-synthesis inhibitor and delayed-treatment efficacy, while providing a useful benchmark for interpreting cell-wall-active antifungal agents.
-
(R)-MG132: A Rigorous Control for Cancer Metabolism
2026-08-27
(R)-MG132 is a functionally inactive MG-132 enantiomer designed to strengthen proteasome inhibition validation. This article shows how it can clarify whether metabolic and post-transcriptional phenotypes, including the HNRNPU–PHGDH axis, are genuinely proteasome-dependent or arise from confounding effects.
-
Hexetidine (NSC-17764): Translational Strategy
2026-08-27
Hexetidine (NSC-17764) offers translational researchers a practical model for studying broad-spectrum oral antimicrobial activity without reducing performance to a single MIC value. This article connects membrane-level biology, adsorption and washout effects, biofilm assay design, and clinical-use considerations to support more predictive oral infection workflows.
-
T7 RNA Polymerase for Precise RNA Synthesis
2026-08-26
T7 RNA Polymerase is a recombinant enzyme expressed in E. coli that selectively transcribes RNA from DNA templates carrying a T7 promoter. Its defined template requirements support in vitro transcription, RNA vaccine production, antisense RNA and RNAi research, and RNA structure-function studies.